prostaglandin-d2 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

prostaglandin-d2 has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies

Other Studies

1 other study(ies) available for prostaglandin-d2 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

Article	Year
Activation of PPARγ by endogenous prostaglandin J Blood, 2017, 03-30, Volume: 129, Issue:13 Supplementation with nontoxic doses of micronutrient selenium has been shown to alleviate chronic myelogenous leukemia (CML) via the elimination of leukemia stem cells (LSCs) in mice. This treatment provides a new and novel method for eliminating the LSCs that are otherwise not targeted by existing therapies. The antileukemic effect of selenium was dependent on the production of endogenous cyclopentenone prostaglandins (CyPGs), Δ-12 prostaglandin J Topics: Animals; Antineoplastic Agents; Dietary Supplements; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; PPAR gamma; Prostaglandin D2; Selenium	2017

Article

Year

Activation of PPARγ by endogenous prostaglandin J

Blood, 2017, 03-30, Volume: 129, Issue:13

Supplementation with nontoxic doses of micronutrient selenium has been shown to alleviate chronic myelogenous leukemia (CML) via the elimination of leukemia stem cells (LSCs) in mice. This treatment provides a new and novel method for eliminating the LSCs that are otherwise not targeted by existing therapies. The antileukemic effect of selenium was dependent on the production of endogenous cyclopentenone prostaglandins (CyPGs), Δ-12 prostaglandin J

Topics: Animals; Antineoplastic Agents; Dietary Supplements; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; PPAR gamma; Prostaglandin D2; Selenium

2017